Everspin Technologies Inc
Change company Symbol lookup
Select an option...
MRAM Everspin Technologies Inc
LULU Lululemon Athletica Inc
SSYS Stratasys Ltd
ASTE Astec Industries Inc
NHTC Natural Health Trends Corp
DB Deutsche Bank AG
XPER Xperi Holding Corp
TT Trane Technologies PLC
UAA Under Armour Inc
JBLU JetBlue Airways Corp
Go

Information Technology : Semiconductors & Semiconductor Equipment | Small Cap Blend
Company profile

Everspin Technologies, Inc. is engaged in providing magnetoresistive random-access memory (MRAM) solutions. The MRAM solutions offer non-volatile memory of random-access memory (RAM). The Company delivers solutions for industrial, medical, automotive/transportation, aerospace and data center. The Company’s products include Toggle MRAM, offers products with industry standard interfaces, including Parallel, Serial Peripheral Interface (SPI) and Quad SPI (QSPI) interfaces; Spin-transfer Torque MRAM (STT-MRAM), offer products with standard DDR3 and DDR4 derivative interfaces; and Tunnel Magneto Resistance (TMR) Sensors, offers die-level devices integrated into consumer electronic applications that utilize a three-dimensional (3D) compass.

Closing Price
$4.96
Day's Change
-0.21 (-4.06%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.24
Day's Low
4.93
Volume
(Average)
Volume:
78,141

10-day average volume:
75,393
78,141

Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update

4:35 pm ET May 3, 2021 (Globe Newswire) Print

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, May 7, 2021.

Ocugen will issue a pre-market earnings announcement the same day. Investors are invited to participate on the call using the following details:

Dial-In Number:  (844) 873-7330 (U.S.) or (602) 563-8473 (international)
Conference ID:   9757658
Webcast:         Available in the "Investors" section of the Ocugen website by clicking here and archived for approximately 45 days following the call

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many," and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN(TM) vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:

Ocugen, Inc.

Sanjay Subramanian

CFO and Head of Corp. Dev.

IR@Ocugen.com

Media Contact:

LaVoieHealthScience

Lisa DeScenza

ldescenza@lavoiehealthscience.com

+1 978-395-5970

https://ml.globenewswire.com/media/163cce64-f2fe-4170-bdba-c5b9826bb921/small/ocugen-logo-color-png.png

https://ml.globenewswire.com/media/163cce64-f2fe-4170-bdba-c5b9826bb921/small/ocugen-logo-color-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.